Double inherited thrombophilias and adverse pregnancy outcomes: Fashion or science?

Journal of Obstetrics and Gynaecology Research

Volumn 36, Issue 5, 2010, Pages 996-1002

  Larciprete, Giovanni ^a   Rossi, Federica ^b   Deaibess, Therese ^c   Brienza, Letizia ^c   Barbati, Giulia ^d   Romanini, Elisabetta ^a   Gioia, Stefano ^e   Cirese, Elio ^a  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e ASL Vallecamonica Sebino   (Italy)

Author keywords

adverse pregnancy outcome; inherited thrombophilias

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; HOMOCYSTEINE; LIVER ENZYME; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PROTEIN S; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DELIVERY; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; FETOPLACENTAL UNIT; GENE MUTATION; HELLP SYNDROME; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREGNANT WOMAN; RECURRENT ABORTION; RETROSPECTIVE STUDY; SOLUTIO PLACENTAE; THROMBOPHILIA;

ABRUPTIO PLACENTAE; ADULT; FACTOR V; FEMALE; FETAL DEATH; FETAL GROWTH RETARDATION; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREGNANCY; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; THROMBOPHILIA;

EID: 77957576416     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2010.01262.x     Document Type: Article

References (28)

1. Tranquilli AR, Giannubilo SR, Dell'Uomo B, Grandone E. Adverse pregnancy outcomes are associated with multiple maternal thrombophilic factors. Eur J Obstet Gynecol Reprod Biol 2004 117 : 144 147.
2. Rongioletti M, Baldassini M, Papa F et al. Homocysteinemia is inversely correlated with platelet count and directly correlated with sE- and sP-selectin levels in females homozygous for C677T methylenetetrahydrofolate reductase. Platelets 2005 16 : 185 190.
3. Hoffman M. Excess factor VIII and hypercoagulability. J Am Board Fam Pract 2005 18 : 328.
4. de Visser MC, Poort SR, Vos HL, Rosendaal FR, Bertina RM. Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis. Thromb Haemost 2001 85 : 1011 1017.
5. Kupferminc MJ, Eldor A, Steinman N et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999 340 : 9 13.
6. Norris LA, Higgins JR, Darling MRN, Walshe JJ, Bonnar J. Nitric oxide in the uteroplacental, fetoplacental, and peripheral circulations in preeclampsia. Obstet Gynecol 1999 93 : 958 963.
7. Kupferminc MJ. Thrombophilia and pregnancy. Reprod Biol Endocrinol 2003 1 : 111.
8. Lenfant C, Gifford RW Jr., Zuspan F. National High Blood Pressure on Education Program Working Group report on high blood pressure in pregnancy. Consensus report. Am J Obstet Gynecol 1990 163 : 1689 1712.
9. Levi M, De Jonge E, Meijers J. The diagnosis of disseminated intravascular coagulation. Blood Rev 2002 16 : 217 223.
10. D'Angelo A, Coppola A, Madonna P et al. The role of vit. B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. A case-control study of patients with early onset thrombotic events. Thromb Haemost 2000 83 : 563 570.
11. Ames PR, Tommasino C, D'Andrea G, Iannaccone L, Brancaccio V, Margaglione M. Thrombophilic genotypes in subjects with idiopathic antiphospholipid antibodies-prevalence and significance. Thromb Haemost 1998 79 : 46 49.
12. Ames PR, Pyke S, Iannaccone L, Brancaccio V. Antiphospholipid antibodies, haemostatic variables and thrombosis (1998) a survey of 144 patients. Thromb Haemost 1995 73 : 768 773.
13. Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994 343 : 1536 1538. (Pubitemid 24180052)
14. Dizon-Towson D, Meline L, Nelson LM, Varner M, Ward K. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol 1997 177 : 402 405.
15. Alfirevic Z, Roberts D, Martlew W. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002 101 : 6 14.
16. Larciprete G, Gioia S, Angelucci PA et al. Single inherited thrombophilias and adverse pregnancy outcomes. J Obstet Gynaecol Res 2007 33 : 423 430.
17. Ricker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of Factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA 1997 277 : 1305 1307.
18. Sohda S, Arinami T, Hamada H, Yamada N, Hamaguchi H, Kubo T. Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet 1997 34 : 525 526.
19. Brattström L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis. Circulation 1998 98 : 2520 2526.
20. Van Der Put NM, Gabreëls F, Stevens EM et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998 62 : 1044 1051. (Pubitemid 28199004)
21. Astedt B, Lindoff C, Lecander I. Significance of the plasminogen activator inhibitor of placental type (PAI-2) in pregnancy. Semin Thromb Hemost 1998 24 : 431 435.
22. Kruithof EKO, Tran-Thang C, Gudinchet A et al. Fibrinolysis in pregnancy: A study of plasminogen activator inhibitor. Blood 1987 69 : 460 466.
23. de Boer K, Lecander I, ten Cate JW et al. Placental type plasminogen activator inhibitor in preeclampsia. Am J Obstet Gynecol 1988 158 : 418 422.
24. Lindoff C, Astedt B. Plasminogen activator of urokinase type and its inhibitor of placental type in hypertensive pregnancies and in intrauterine growth retardation: possible markers of placental function. Am J Obstet Gynecol 1994 171 : 60 64.
25. Gerhardt A, Goecke TW, Beckmann MW et al. The G20210A prothrombin-gene mutation and the plasminogen activator inhibitor (PAI-1) 5G/5G genotype are associated with early onset of severe preeclampsia. J Thromb Haemost 2005 3 : 686 691.
26. Li D, Pickell L, Liu Y, Wu Q, Cohn JS, Roze R. Maternal methylenetetrahydrofolate reductase deficiency and low dietary folate lead to adverse reproductive outcomes and congenital heart defects in mice. Am J Clin Nutr 2005 82 : 188 195.
27. Wu O, Robertson L, Twaddle S et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006 10 : 1 110.
28. Mutze S, Rudnik-Schoneborn S, Zerres K, Rath W. Genes and the preeclampsia syndrome. J Perinat Med 2008 36 : 38 58.